Allopurinol and Pathogenesis of Cirrhosis

November 3, 2026 updated by: Khadija Ahmed Mhrose Glal, Tanta University

Allopurinol Interferes With the Pathological Mechanisms of Hepatic Decompensation

Hepatic decompensation is a common healthcare issue

. This study was conducted to investigate how allopurinol can interfere with the pathological mechanisms of HD.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

110

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Tanta, Egypt
        • Tanta University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • age 18-75 both sex

Exclusion Criteria:

  • active GIT bleeding

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: allopurinol
Drug: Allopurinol Tablet

allopurinol 300
Placebo Comparator: placebo

placebo
Drug: Placebo

placebo tablet

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Levels of gut barrier and microbial translocation biomarkers, including zonulin, lipopolysaccharide (LPS), NFκB, MMP-13, and malondialdehyde (MDA), measured in serum/plasma.
Time Frame: 6 MONTHS

Levels of gut barrier and microbial translocation biomarkers, including zonulin, lipopolysaccharide (LPS), NFκB, MMP-13, and malondialdehyde (MDA), measured in serum/plasma.
6 MONTHS

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Tanta University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 15, 2022

Primary Completion (Actual)

February 15, 2023

Study Completion (Actual)

March 1, 2023

Study Registration Dates

First Submitted

June 14, 2025

First Submitted That Met QC Criteria

June 14, 2025

First Posted (Actual)

June 24, 2025

Study Record Updates

Last Update Posted (Actual)

November 4, 2026

Last Update Submitted That Met QC Criteria

November 3, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ALLOU

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe